Bjørn-Eivind Kirsebom
Stillingsbeskrivelse
Forskning, undervisning og veiledning innen klinisk nevropsykologi/nevrologi med spesielt fokus på demenssykdomer.
Leder Dementia Disease Initiation (DDI) avd. Tromsø.
Mostafa Mehdipour Ghazi,
Per Selnes,
Santiago Timon Reina,
Sandra Raquel Ramos Teceläo,
Silvia Ingala,
Atle Bjørnerud
m.fl.:
Comparative analysis of multimodal biomarkers for amyloid-beta positivity detection in Alzheimer's disease cohorts
Cecilia Magdalena Eriksson,
Bjørn-Eivind Seljelid Kirsebom,
Ragna Espenes,
Nikias Ioannis Siafarikas,
Knut Waterloo,
Arvid Rongve
m.fl.:
Depressive Symptoms Are Not Associated with Predementia Cerebrospinal Fluid Amyloid Pathology
Anders Wimo,
Bjørn-Eivind Seljelid Kirsebom,
Santiago Timon Reina,
Ellen Vromen,
Per Selnes,
Jaka Bon
m.fl.:
Costs of diagnosing early Alzheimer's disease in three European memory clinic settings: Results from the precision medicine in Alzheimer's disease project
Stephanie Knudtzon,
Kaja Nordengen,
Gøril Rolfseng Grøntvedt,
Jonas Alexander Jarholm,
Ingvild Vøllo Eliassen,
Per Selnes
m.fl.:
Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer’s Disease
Fernando Gonzalez-Ortiz,
Bjørn-Eivind Seljelid Kirsebom,
José Contador,
Jordan E. Tanley,
Per Selnes,
Berglind Gisladottir
m.fl.:
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
Sofia Egebäck Arulf,
Robin Ziyue Zhou,
Bjørn-Eivind Seljelid Kirsebom,
Alenka Jejcic,
Tormod Fladby,
Bengt Winblad
m.fl.:
Bisecting N-Acetylglucosamine Correlates with Phospho-Tau181 in Subjective Cognitive Decline but not in Control Cases
Journal of Alzheimer's Disease 2024 DOI
Fernando Gonzalez-Ortiz,
Thomas K. Karikari,
Danielle Taylor-Te Vruchte,
Dawn Shepherd,
Bjørn-Eivind Seljelid Kirsebom,
Tormod Fladby
m.fl.:
Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C
Brain Communications 2024 DOI
Julia Kristine Gundersen,
Fernando Gonzalez-Ortiz,
Thomas Karikari,
Bjørn-Eivind Seljelid Kirsebom,
Katrin Mertes,
Henrik Zetterberg
m.fl.:
Neuronal plasma biomarkers in acute ischemic stroke
Journal of Cerebral Blood Flow and Metabolism 2024 DOI
Therese Händel Waggestad,
Bjørn-Eivind Kirsebom,
Carsten Strobel,
Anders Wallin,
Marie Eckerström,
Tormod Fladby
m.fl.:
Improving validity of the trail making test with alphabet support
Santiago Timón,
Mariano Rincón,
Rafael Martínez-Tomás,
Bjørn-Eivind Seljelid Kirsebom,
Tormod Fladby
:
A Knowledge Graph Framework for Dementia Research Data
Klaus Thanke Aspli,
Jan Aaseth,
Trygve Holmøy,
Kaj Blennow,
Henrik Zetterberg,
Bjørn-Eivind Seljelid Kirsebom
m.fl.:
CSF, Blood, and MRI Biomarkers in Skogholt’s Disease—A Rare Neurodegenerative Disease in a Norwegian Kindred
Mathilde Suhr Hemminghyth,
Luiza Chwiszczuk,
Monica Haraldseid Breitve,
Berglind Gisladottir,
Gøril Rolfseng Grøntvedt,
Arne Exner Nakling
m.fl.:
Cerebrospinal fluid neurofilament light chain mediates age-associated lower learning and memory in healthy adults
Fredrik Öhman,
Marie Eckerström,
Erik Hessen,
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Ingrid Myrvoll Lorentzen
m.fl.:
Demographically adjusted Rey–Osterrieth Complex Figure Test norms in a Swedish and Norwegian cohort aged 49–77 years and comparison with North American norms
Ingrid Myrvoll Lorentzen,
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Erik Hessen,
Knut K Waterloo,
Arne Exner Nakling
m.fl.:
Investigating the relationship between allocentric spatial working memory and biomarker status in preclinical and prodromal Alzheimer’s disease
Johan Jacob Espenes,
Ingrid Myrvoll Lorentzen,
Ingvild Vøllo Eliassen,
Erik Hessen,
Knut K Waterloo,
Santiago Timón
m.fl.:
Regression-based normative data for the D-KEFS Color-Word Interference Test in Norwegian adults ages 20–85
Jonas Alexander Jarholm,
Atle Bjørnerud,
Turi Olene Dalaker,
Mehdi Sadat Akhavi,
Bjørn-Eivind Kirsebom,
Lene Pålhaugen
m.fl.:
Medial Temporal Lobe Atrophy in Predementia Alzheimer's Disease: A Longitudinal Multi-Site Study Comparing Staging and A/T/N in a Clinical Research Cohort
Kaja Nordengen,
Bjørn-Eivind Seljelid Kirsebom,
Grit Richter,
Lene Pålhaugen,
Berglind Gisladottir,
Nikias Ioannis Siafarikas
m.fl.:
Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease
Miguel Germán Borda,
Daniel Ferreira,
Per Selnes,
Diego Alejandro Tovar-Rios,
Alberto Jaramillo-Jiménez,
Bjørn-Eivind Kirsebom
m.fl.:
Timed Up and Go in People with Subjective Cognitive Decline Is Associated with Faster Cognitive Deterioration and Cortical Thickness
Jacob Espenes,
Ingvild Vøllo Eliassen,
Fredrik Öhman,
Erik Hessen,
Knut K Waterloo,
Marie Eckerström
m.fl.:
Regression‐based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults aged 49–79 and comparison with published norms
Ingvild Vøllo Eliassen,
Bjørn-Eivind Kirsebom,
Tormod Fladby,
Knut Waterloo,
Sigrid Botne Sando,
Mathilde Suhr Hemminghyth
m.fl.:
Regression-Based Cognitive Change Norms Applied in Biochemically Defined Predementia Alzheimer’s Disease
Bjørn-Eivind Kirsebom,
Grit Richter,
Kaja Nordengen,
Dag Aarsland,
Geir Bråthen,
Betty M Tijms
m.fl.:
Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients
Ingrid Myrvoll Lorentzen,
Johan Jacob Espenes,
Erik Hessen,
Knut Waterloo,
Geir Bråthen,
Santiago Timón
m.fl.:
Regression-based norms for the FAS phonemic fluency test for ages 40–84 based on a Norwegian sample
Nikias Ioannis Siafarikas,
Bjørn-Eivind Kirsebom,
Deepak P Srivastava,
Cecilia Magdalena Eriksson,
Eirik Auning,
Erik Hessen
m.fl.:
Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
Ragna Espenes,
Bjørn-Eivind Kirsebom,
Cecilia Magdalena Eriksson,
Knut K Waterloo,
Erik Hessen,
Stein Harald Johnsen
m.fl.:
Amyloid plaques and symptoms of depression links to medical help-seeking due to subjective cognitive decline
Ingvild Vøllo Eliassen,
Tormod Fladby,
Bjørn-Eivind Kirsebom,
Knut Waterloo,
Marie Eckerström,
Anders Wallin
m.fl.:
Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia
Anne Katrine Bergland,
Petroula Proitsi,
Bjørn-Eivind Kirsebom,
Hogne Sønnesyn,
Abdul Hye,
Alf Inge Larsen
m.fl.:
Exploration of plasma lipids in mild cognitive impairment due to Alzheimer's disease
Journal of Alzheimer's Disease 2020 DOI
Johan Jacob Espenes,
Erik Hessen,
Ingvild Vøllo Eliassen,
Knut Waterloo,
Marie Eckerström,
Sigrid Botne Sando
m.fl.:
Demographically adjusted trail making test norms in a Scandinavian sample from 41 to 84 years
Bjørn-Eivind Kirsebom,
Ragna Espenes,
Erik Hessen,
Knut Waterloo,
Stein Harald Johnsen,
Elisabeth Gundersen
m.fl.:
Demographically adjusted CERAD wordlist test norms in a Norwegian sample from 40 to 80 years
Kaja Nordengen,
Bjørn-Eivind Kirsebom,
Kristi Henjum,
Per Selnes,
Berglind Gisladottir,
Marianne Wettergreen
m.fl.:
Glial activation and inflammation along the Alzheimer's disease continuum
Erik Hessen,
Bjørn-Eivind Kirsebom,
Cecilia Magdalena Eriksson,
Carl Fredrik Andestad Eliassen,
Arne Nakling,
Geir Bråthen
m.fl.:
In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion
Bjørn-Eivind Kirsebom,
Kaja Nordengen,
Per Selnes,
Knut Waterloo,
Silje Bøen Torsetnes,
Berglind Gisladottir
m.fl.:
Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
Tormod Fladby,
Lene Pålhaugen,
Per Selnes,
Knut Waterloo,
Geir Bråthen,
Erik Hessen
m.fl.:
Detecting at-risk Alzheimer's disease cases
Journal of Alzheimer's Disease 29. august 2017 DOI
Bjørn-Eivind Seljelid Bordewic Kirsebom,
Ragna Espenes,
Knut Waterloo,
Erik Hessen,
Stein Harald Johnsen,
Geir Bråthen
m.fl.:
Screening for Alzheimer’s Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients
Luiza Chwiszczuk,
Monica Haraldseid Breitve,
Bjørn-Eivind Kirsebom,
Per Selnes,
John Christian Jøraholmen Fløvig,
Anne Brita Knapskog
m.fl.:
The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial
Mathilde Suhr Hemminghyth,
Monica Haraldseid Breitve,
Berglind Gisladottir,
Gøril Rolfseng Grøntvedt,
Arne Exner Nakling,
Tormod Fladby
m.fl.:
Cerebrospinal fluid neurofilament light chain mediates age-related decline in learning and memory in healthy adults
2023
Nikias Ioannis Siafarikas,
Bjørn-Eivind Kirsebom,
Deepak P. Srivastava,
Cecilia Magdalena Eriksson,
Eirik Auning,
Erik Hessen
m.fl.:
Author Correction: Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression (Scientific Reports, (2021), 11, 1, (20375), 10.1038/s41598-021-99794-9)
Scientific Reports 2022 DOI
Bjørn-Eivind Kirsebom
:
Hva vet vi om Alzheimers sykdom i dag, og finnes det en kur?
Nordlys 21. september 2020 DATA
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Tormod Fladby,
Marie Eckerström,
Wallin Anders,
Knut Waterloo
m.fl.:
Demographically adjusted test norms for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults
from 41 to 79 years
2020
Grit Richter,
Bjørn-Eivind Kirsebom,
Per Selnes,
Kaja Nordengen,
Knut Waterloo,
Berglind Gisladottir
m.fl.:
Early increase in CSF neurogranin/BACE1 ratio in predementia APOE-ɛ4 homozygote cases with amyloid pathology
2019
Johan Jacob Espenes,
Bjørn-Eivind Kirsebom,
Ingvild Eliassen Vøllo,
Ragna Espenes,
Knut Waterloo,
Erik Hessen
m.fl.:
Demographically adjusted norms for basic and derived measures on the Trail Making Test A & B based on a Norwegian sample age 40 – 84 years.
2019
Bjørn-Eivind Kirsebom
:
Vil avdekke Alzheimers sykdom så tidlig som mulig
05. juni 2019
Bjørn-Eivind Kirsebom,
Per Selnes,
Grit Richter,
Berglind Gisladottir,
Marianne Wettergreen,
Silje Bøen Torsetnes
m.fl.:
Cerebrospinal fluid Neurogranin/BACE1 ratio differentiate normal controls, pre-dementia Alzheimer’s and Parkinson’s disease cases.
2019
Ragna Espenes,
Bjørn-Eivind Kirsebom,
Cecilia Magdalena Eriksson,
Knut Waterloo,
Stein Harald Johnsen,
Erik Hessen
m.fl.:
Medical help-seeking in Subjective Cognitive Decline associated with lower CSF Aβ1-42 and reduced memory performance
2019
Ingvild Vøllo Eliassen,
Bjørn-Eivind Kirsebom,
Erik Hessen,
Per Selnes,
Knut Waterloo,
Tormod Fladby
:
Distractor List Errors from Verbal Learning Test May Reveal Deficient Temporal Memory Encoding in Predementia Alzheimer’s Disease
2019
Bjørn-Eivind Kirsebom
:
Frykter fordobling av demenstilfeller innen 2050: Tromsø-forskere undersøker om blåbær kan være kuren
14. august 2019 DATA
Grit Richter,
Bjørn-Eivind Kirsebom,
Per Selnes,
Kaja Nordengen,
Knut Waterloo,
Berglind Gisladottir
m.fl.:
An amyloid-coupled pre-dementia increased CSF neurogranin/BACE1 ratio may reflect early synapse affection in APOE-ɛ4 homozygotes
2019
Bjørn-Eivind Kirsebom,
Tine Viktoria Buberg
:
Forsker på demens: – Antioksidanter fra blåbær kan bidra til å bremse demens
07. august 2019
Bjørn-Eivind Kirsebom
:
Tromsø-forskere jobber intenst med å løse alzheimer-gåten
28. desember 2019
Bjørn-Eivind Kirsebom,
Kaja Nordengen,
Per Selnes,
Knut Waterloo,
Britta Brix,
Eugeen Vanmechelen
m.fl.:
INCREASED CSF NEUROGRANIN/BACE1 RATIO IN AMYLOID POSITIVE SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE
2018
Bjørn-Eivind Kirsebom,
Ragna Espenes,
Knut Waterloo,
Stein Harald Johnsen,
Tormod Fladby
:
Screening for Alzheimer's Disease: Cognitive Impairent in Self-Referred and Memory Clinic-Referred Patients
2017
De 50 siste resultatene fra Cristin vises på siden. Se alle arbeider i Cristin her →
Forskningsinteresser
Klinisk nevropsykologi og regresjonsbaserte normer. Preklinisk og prodromal Alzheimers sykdom.